Head and Neck Cancer, Non Small Cell Lung Carcinoma NSCLC, Prostate Cancer
Conditions
Keywords
Whole body PET scanner, 26-227
Brief summary
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Detailed description
This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.
Interventions
DIAGNOSTIC_TESTBiograph Vision Quadra scanner
new total-body PET scanner, 1 or 2 additional scans with the Biograph Vision Quadra scanner.
DIAGNOSTIC_TESTPET/CT
Scheduled PET/CT scan
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Eligibility Criteria for objective #1: * Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules. * Patients who are undergoing a planned PET-CT scan at main campus of MSK. * Patients must be ≥ 18 years old Eligibility Criteria for objective #2: * Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously. * Patients with metastatic prostate or head and neck cancer. * Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK. * Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK * Patients must be ≥ 18 years old Eligibility Criteria for objective #3: * Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer). * Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK. * Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection) * Patients must be ≥ 18 years old
Exclusion criteria
* Patients who suffer from claustrophobia. * Women who are pregnant or breast-feeding. * Patients \< 18 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| image quality | 3 years | Detection of any new/additional lesions on the delayed scan will be recorded using standard clinical interpretation. |
Countries
United States
Contacts
CONTACTHeiko Schoder, MD
CONTACTJohn Humm, PhD
PRINCIPAL_INVESTIGATORHeiko Schoder, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed